Back to results
US 7,744,875 B2Granted
Surrogate therapeutic endpoint for anti-CTLA-4 based immunotherapy of disease
AssigneeMedarex, Inc.
InventorsIsrael Lowy, Geoffrey M. Nichol
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided.
Claims10
A method for determining a therapeutically effective dosage regimen of anti-CTLA -4 antibody for the treatment of cancer, which method comprises adjusting a dose or dosage schedule, or both, of an anti-CTLA-4 antibody in a subject until observing a breakthrough event in the subject, which dose is the therapeutically effective dosage regimen.
Dependencies are inferred from the claim text.